Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. Sapena V, et al. Among authors: calleja jl. Gut. 2022 Mar;71(3):593-604. doi: 10.1136/gutjnl-2020-323663. Epub 2021 Mar 19. Gut. 2022. PMID: 33741640 Free article.
Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J, Romero-Gómez M, Planas R, Solà R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Rubio-Terrés C, Ventayol P. Turnes J, et al. Among authors: calleja jl. Gastroenterol Hepatol. 2013 Nov;36(9):555-64. doi: 10.1016/j.gastrohep.2013.08.003. Epub 2013 Oct 9. Gastroenterol Hepatol. 2013. PMID: 24119723
Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
Lens S, Rincón D, García-Retortillo M, Albillos A, Calleja JL, Bañares R, Abraldes JG, Bosch J, Sanchez-Tapias JM, Forns X, García-Pagán JC. Lens S, et al. Among authors: calleja jl. Clin Gastroenterol Hepatol. 2015 Oct;13(10):1846-1853.e1. doi: 10.1016/j.cgh.2015.04.013. Epub 2015 Apr 23. Clin Gastroenterol Hepatol. 2015. PMID: 25912838
[Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
Crespo J, Berenguer M, Pérez F, Fernández I, González O, Bárcena R, Buti M, López J, Calleja JL; en representación del grupo de investigadores del estudio LEAD-IN. Crespo J, et al. Among authors: calleja jl. Gastroenterol Hepatol. 2015 Nov;38(9):517-24. doi: 10.1016/j.gastrohep.2015.04.002. Epub 2015 May 12. Gastroenterol Hepatol. 2015. PMID: 25976446 Spanish.
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
Ampuero J, Del Campo JA, Rojas L, Calleja JL, Cabezas J, Lens S, Crespo J, Forns X, Andrade RJ, Fernández I, Buti M, Millán R, Romero-Gómez M. Ampuero J, et al. Among authors: calleja jl. J Clin Virol. 2015 Jul;68:56-60. doi: 10.1016/j.jcv.2015.05.010. Epub 2015 May 14. J Clin Virol. 2015. PMID: 26071337
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Papatheodoridis G, et al. Among authors: calleja jl. J Hepatol. 2016 Apr;64(4):800-6. doi: 10.1016/j.jhep.2015.11.035. Epub 2015 Dec 8. J Hepatol. 2016. PMID: 26678008
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour JF, Van Vlierberghe H, van Hoek B, Forns X; SOLAR-2 investigators. Manns M, et al. Among authors: calleja jl. Lancet Infect Dis. 2016 Jun;16(6):685-697. doi: 10.1016/S1473-3099(16)00052-9. Epub 2016 Feb 18. Lancet Infect Dis. 2016. PMID: 26907736 Clinical Trial.
264 results